Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Utility of Combined Optical Genome Mapping and 523-gene Next Generation Sequencing Panel For Comprehensive Evaluation of Myeloid Cancers

Nikhil Shri Sahajpal, Ashis K Mondal, Sudha Ananth, Daniel Saul, Soheil Shams, Alex R Hastie, Natasha M. Savage, Vamsi Kota, Alka Chaubey, View ORCID ProfileRavindra Kolhe
doi: https://doi.org/10.1101/2022.01.15.22269355
Nikhil Shri Sahajpal
1Department of Pathology, Medical College of Georgia, Augusta University, GA, 30912, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashis K Mondal
1Department of Pathology, Medical College of Georgia, Augusta University, GA, 30912, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudha Ananth
1Department of Pathology, Medical College of Georgia, Augusta University, GA, 30912, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Saul
2Bionano Genomics Inc., San Diego, CA 92121, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soheil Shams
2Bionano Genomics Inc., San Diego, CA 92121, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex R Hastie
2Bionano Genomics Inc., San Diego, CA 92121, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha M. Savage
1Department of Pathology, Medical College of Georgia, Augusta University, GA, 30912, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vamsi Kota
3Department of Medicine and Georgia Cancer Center, Medical College of Georgia, Augusta University, GA, 30912, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alka Chaubey
2Bionano Genomics Inc., San Diego, CA 92121, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravindra Kolhe
1Department of Pathology, Medical College of Georgia, Augusta University, GA, 30912, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ravindra Kolhe
  • For correspondence: rkolhe@augusta.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The standard-of-care (SOC) for genomic testing of myeloid cancers primarily relies on karyotyping and fluorescent in situ hydridization (FISH) (cytogenetic analysis) and targeted gene panels (≤54 genes) that harbor hotspot pathogenic variants (molecular genetic analysis). Both cytogenetic and molecular testing workup is necessary for the identification and detection of large structural variants (SVs) and small variants like single nucleotide variants (SNV) and indels, respectively. Despite this combinatorial approach, ∼50% of myeloid cancer genomes remain cytogenetically normal, and the limited sequencing variant profiles obtained from targeted panels are unable to resolve the genetic etiology of these myeloid tumors. In this study, we evaluated the performance and clinical utility of optical genome mapping (OGM) and a 523-gene next-generation sequencing (NGS) panel for comprehensive genomic profiling of 15 myeloid tumors and compared it to SOC cytogenetic methods (karyotyping and FISH) and a 54-gene NGS panel. OGM and the 523-gene NGS panel were found to have an analytical concordance of 100% with karyotyping, FISH, and the 54-gene panel, respectively. Additionally, OGM better characterized and resolved the structural variants previously reported by karyotyping in five cases, such as identifying the genomic content of marker and ring chromosomes. OGM also identified several additional translocations and eleven copy number variations (CNVs), of which the CNVs were validated/confirmed by the 523-gene panel. The 523-gene panel identified seven additional clinically relevant SNVs (two tier 1A variants and five tier 2C variants, as per the ACMG/AMP guidelines) in four cases. The simultaneous visualization of SVs and small NGS detected sequence variants (SNVs and small indels) from OGM and 523-gene NGS panel, respectively in the NxClinical software v6.1 identified two clinically relevant compound heterozygous events in two samples. This study demonstrates the higher sensitivity, resolution, accuracy, and ability to reveal cryptic and clinically relevant novel variants in myeloid cancers as compared to SOC methodologies. Our cost-effective approach of using OGM and a 523-gene NGS panel for comprehensive genomic profiling of myeloid cancers will not only increase the yield of actionable targets leading to improved clinical outcomes but also help resolve our ongoing conundrum of apparently genomically normal myeloid cancers by providing more answers.

Competing Interest Statement

RK has received honoraria, and/or travel funding, and/or research support from Illumina, Asuragen, QIAGEN, Perkin Elmer Inc, Bionano Genomics, Agena, Agendia, PGDx, Thermo Fisher Scientific, Cepheid, and BMS. DS, SS, AH, and AC are salaried employee at Bionano Genomics Inc. All other authors have no competing interests to disclose.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the IRB A- BIOMEDICAL I (IRB REGISTRATION #00000150), Augusta University. HAC IRB # 611298. Based on the IRB approval, the need for consent was waived; all PHI was removed, and all data was anonymized before accessing for the study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All relevant data has been included in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted January 17, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Utility of Combined Optical Genome Mapping and 523-gene Next Generation Sequencing Panel For Comprehensive Evaluation of Myeloid Cancers
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Utility of Combined Optical Genome Mapping and 523-gene Next Generation Sequencing Panel For Comprehensive Evaluation of Myeloid Cancers
Nikhil Shri Sahajpal, Ashis K Mondal, Sudha Ananth, Daniel Saul, Soheil Shams, Alex R Hastie, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Ravindra Kolhe
medRxiv 2022.01.15.22269355; doi: https://doi.org/10.1101/2022.01.15.22269355
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Clinical Utility of Combined Optical Genome Mapping and 523-gene Next Generation Sequencing Panel For Comprehensive Evaluation of Myeloid Cancers
Nikhil Shri Sahajpal, Ashis K Mondal, Sudha Ananth, Daniel Saul, Soheil Shams, Alex R Hastie, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Ravindra Kolhe
medRxiv 2022.01.15.22269355; doi: https://doi.org/10.1101/2022.01.15.22269355

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (492)
  • Occupational and Environmental Health (568)
  • Oncology (1324)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)